Navigation Links
S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
Date:9/10/2007

SINGAPORE, Sept. 11 /PRNewswire/ -- S*BIO Pte Ltd today announced the development of a novel and proprietary orally-administered compound, SB1518, for the treatment of myeloproliferative disorders (MPD) and certain hematological malignancies. MPD is believed to be caused by a specific mutation (V617F) of JAK2 and is a closely related group of hematological malignancies in which the bone marrow develops and functions abnormally. MPD is characterised by an excess of blood cells and the three main disorders include polycythemia vera (excess red blood cell mass), essential thrombocythemia (excess blood platelets) and myelofibrosis. S*BIO is a privately-held biotech company focusing on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer.

SB1518 is a small molecule JAK2-selective kinase inhibitor. It has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the activating V617F mutation which is found in high frequencies among three types of MPD and in some leukemias. By targeting the JAK2 activating mutation, SB1518 has the potential to interfere with a key mechanism driving the progress of MPD and other diseases.

"SB1518 has demonstrated excellent anti-proliferative and anti-tumor activity, combined with very good tolerability in relevant in vitro and in vivo models. SB1518 will address an important unmet medical need due to the lack of specific and effective long-term medical treatment for patients with MPD," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "This promising new compound is our second success in the last twelve months and represents an important step in building S*BIO's strong pipeline of proprietary, targeted anti-cancer compounds."

In addition to SB1518, S*BIO has a robust pipeline including SB939, the company's lead histone deacetylase (HDAC) inhibitor which is currently in Phase 1 clinical trials. S*BIO's target-driven approach to innovative small molecule therapies for cancer is built on a profound understanding of cancer biology, which the company aggressively translates into "best-in-class" and "first-in-class" drugs. The company has a strong team of experienced drug discovery scientists and biologists, and state-of-the-art infrastructure which includes a comprehensive technology platform covering the drug discovery value chain, from target identification and validation through lead optimisation to pre-clinical and clinical development.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. Its lead candidate, SB939, has entered the clinic in 2Q 2007.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong linkages with a network of medical oncologists in Asia Pacific. More information about S*BIO can be found at http://www.sbio.com.

S*BIO Pte Ltd: Russo Partners:

Stephen Keith Rhind, Ph.D. Tony Russo +1 212-845-4251

Senior Vice President, Tony.Russo@russopartnersllc.com

Corporate Development Andreas Marathovouniotis +1 212-845-4253

Tel: +65 6827 5000 (Singapore) Andreas.Marathis@russopartnersllc.com

Stephen_rhind@sbio.com


'/>"/>
SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
3. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
4. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
5. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
6. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
7. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
8. CuraGen Presents Update on Clinical Development Program for Belinostat
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
11. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of sub-acute ... of a disaster drill on October 3rd. , Apple Rehab participated with the Shelton ... well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The LTC-MAP ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
Breaking Medicine News(10 mins):